Open Access

Effect of erlotinib combined with cisplatin on IL‑6 and IL‑12 in mice with Lewis lung cancer

  • Authors:
    • Xu Zhang
    • Jinliang Chen
    • Hongsong Jin
    • Wei Zhao
    • Zhibo Chang
    • Huijing Wu
  • View Affiliations

  • Published online on: May 18, 2020     https://doi.org/10.3892/ol.2020.11632
  • Pages: 902-906
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Effect of erlotinib combined with cisplatin on tumor growth, interleukin‑6 (IL‑6) and interleukin‑12 (IL‑12) in mice with Lewis lung cancer (LLC) was investigated. Forty‑four pure inbred SPF C57BL/6J mice were modeled for LLC and randomized into groups A, B, C and D (n=11 each group). Mice in group A were given normal saline, group B was given erlotinib, group C was given cisplatin injection and group D erlotinib combined with cisplatin. Tumor growth of the mice was observed and the tumor mass was measured. Serum IL‑6 and IL‑12 levels were measured by enzyme‑linked immunosorbent assay (ELISA) 40 days later. At different time‑points after medication, tumor volume in group D was significantly lower than that in groups A, B and C (P<0.05), and that in groups B and C was significantly lower than that in group A (P<0.05), whereas there was no significant difference between groups B and C (P>0.05). Tumor mass in groups B, C and D was significantly lower than that in group A (P<0.05), and that in group D was significantly lower than that in groups B and C (P<0.05), whereas there was no significant difference between groups B and C (P>0.05). Compared with groups B and C, mice in group D had significantly lower IL‑6 level (P<0.05), but significantly higher IL‑12 level (P<0.05). There was no significant difference in IL‑6 and IL‑12 levels between groups B and C (P>0.05). In conclusion, erlotinib combined with cisplatin can inhibit the tumor growth of mice with LLC, and inhibition of IL‑6 level and upregulation of IL‑12 level may be one of its therapeutic mechanisms.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhang, X., Chen, J., Jin, H., Zhao, W., Chang, Z., & Wu, H. (2020). Effect of erlotinib combined with cisplatin on IL‑6 and IL‑12 in mice with Lewis lung cancer. Oncology Letters, 20, 902-906. https://doi.org/10.3892/ol.2020.11632
MLA
Zhang, X., Chen, J., Jin, H., Zhao, W., Chang, Z., Wu, H."Effect of erlotinib combined with cisplatin on IL‑6 and IL‑12 in mice with Lewis lung cancer". Oncology Letters 20.1 (2020): 902-906.
Chicago
Zhang, X., Chen, J., Jin, H., Zhao, W., Chang, Z., Wu, H."Effect of erlotinib combined with cisplatin on IL‑6 and IL‑12 in mice with Lewis lung cancer". Oncology Letters 20, no. 1 (2020): 902-906. https://doi.org/10.3892/ol.2020.11632